Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: A new therapeutic approach to disease progression and recurrence

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 2, 2014, Pages 52-68

  Crawford, Sarah ^a  

^a SOUTHERN CONNECTICUT STATE UNIVERSITY   (United States)

Author keywords

anti inflammatory agents; antioxidants; chemotherapy; long term maintenance cancer therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AXITINIB; BEVACIZUMAB; BOSUTINIB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; DASATINIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IPILIMUMAB; LAPATINIB; NILOTINIB; PANITUMUMAB; PAZOPANIB; PONATINIB; REACTIVE OXYGEN METABOLITE; REGORAFENIB; RUXOLITINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOFACITINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RECURRENCE; CANCER THERAPY; CHEMOPROPHYLAXIS; COLON CANCER; HUMAN; INFLAMMATION; LONG TERM CARE; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84899071584     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014521111     Document Type: Review

References (98)

1. Achuthan S. Santhoshkumar T. Prabhakar J. Nair S. Pillai M. (2011) Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem 286: 37813–37829.
2. Anderson W. Umar A. Viner J. Hawk E. (2002) The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 8: 1035–1062.
3. Annemijn M. Algra B. Rothwell P. (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet 13: 518–527.
4. Baek J. Eling T. (2006) Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog Lipid Res 45: 1–16.
5. Bastiaannet E. Sampieri K. Dekkers O. de Craen A. van Herk-Sukel M. Lemmens V. et al. (2012) Use of aspirin postdiagnosis improves survival for colon cancer patients Br J Cancer 106: 1564–1570.
6. Bjelakovic G. Nikolova D. Gluud L. Simonetti R. Gluud C. (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297: 842–857.
7. Bjelakovic G. Nikolova D. Gluud L. Simonetti R. Gluud C. (2012) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev CD007176. doi: 10.1002/14651858.CD007176.pub2.
8. Block K. (2004) Antioxidants and cancer therapy: furthering the debate. Integr. Cancer Ther 3: 342–348.
9. Bonuccelli G. Tsirigos A. Whitaker-Menezes D. Pavlides S. Pestell R. Chiavarina B. et al. (2010 a) Ketones and lactate ‘fuel‘ tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9: 3506–3514.
10. Bonuccelli G. Whitaker-Menezes D. Castello-Cros R. Pavlides S. Pestell R. Fatatis A. et al. (2010 b) The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 9: 1960–1971.
11. Boucher Y. Baxter L. Jain R. (1990) Interstitial pressure gradients in tissue isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478–4484.
12. Brown J. Wilson W. (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437–447.
13. Burn J. Gerdes A. Macrae F. Mecklin J. Moeslein G. Olschwang S. et al. (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP 2 randomised controlled trial. Lancet 378: 2081–2087.
14. Castelao J. Yuan J. Gago-Dominguez M. Yu M. Ross R. (2000) Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364–1369.
15. Chan A. Lippman S. (2011) Aspirin and colorectal cancer prevention in Lynch syndrome. Lancet 378: 2051–2052.
16. Chan A. Ogino S. Fuchs C. (2009)Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649–658.
17. Chandrasekaran S. King M. (2012) Gather round: in vitro tumor spheroids as improved models of in vivo tumors. J Bioengineer Biomed Sci 2: e109. doi:10.4172/2155-9538.1000e109.
18. Chlebowski R. Johnson K. Kooperberg C. Pettinger M. Wactawski-Wende J. Rohan T. et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Nat Can Inst 100: 1581–1591.
19. Choe K. Cowan J. Chan J. Carroll P. D'Amico A. Liauw S. (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 30: 3540–3544.
20. Cole B. Logan R. Halabi S. Benamouzig R. Sandler R. Grainge M. et al. (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomised trials. J Natl Cancer Inst 101: 256–266.
21. Cook N. Lee I. Gaziano J. Gordon D. Ridker P. Manson J. et al. (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomised controlled trial. JAMA 294: 47–55.
22. Coussens L. Werb Z. (2002) Inflammation and cancer. Nature 420: 860–867.
23. Crawford S. (2013) Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol 4: 68.
24. D'Andrea G. (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 55: 319–321.
25. de Lorenze G. McCoy L. Tsai A. Quesenberry C. Rice T. Il'yasova D. et al. (2010) Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma. BMC Cancer 19: 210–215.
26. Di Vizio D. Morello M. Sotgia F. Pestell R. Freeman M. Lisanti M. (2009) An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 8: 2420–2424.
27. Duan H. Zhang H. Yang J. Oberley L. Futscher B. Domann F. (2003) MnSOD upregulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxid Redox Signal 5: 677–688.
28. Early Breast Cancer Trialists’ Collaborative Group, Davies C. Godwin J. Gray R. Clarke M. Cutter D. Darby S. et al. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771–784.
29. Farrow B. Evers B. (2002) Inflammation and the development of pancreatic cancer. Surg Oncol 10: 153–169.
30. Finak G. Bertos N. Pepin F. Sadekova S. Souleimanova M. Zhao H. et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518–527.
31. Fleet J. Desmet M. Johnson R. Li Y. (2012) Vitamin D and cancer: a review of molecular mechanisms Biochem J 441: 61–76.
32. Greenlee H. Kwan M. Kushi L. Song J. Castillo A. Weltzein E. et al. (2012) Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. Cancer 118: 2048–2058.
33. Gupta S. Hevia D. Patchva S. Park B. Koh W. Bharat Aggarwal B. (2012) Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 16: 1295–1322.
34. Hatse S. Lambrechts D. Wilders H. (2012) Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 33: 1319–1328.
35. Higgins M. Chapman J. Ingle J. Sledge G. Budd G. Ellis M. et al. (2012) Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in post-menopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. Cancer Res 72: S3 (abstract).
36. Holmes M. Chen W. Li L. Hertzmark E. Spiegelman D. Hankinson S. (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467–1472.
37. Howlader N. Noone A. Krapcho M. Neyman N. Aminou R. Altekruse S. et al. (eds) (2011) SEER Cancer Statistics Review, 1975–2009. Vintage 2009 Populations. Bethesda, MD: National Cancer Institute.
38. Huang M. Lou Y. Ma W. (1994) Inhibitory effect of dietary curcumin on forestomach, duodenal and colon carcinogenesis in mice. Cancer Res 54: 5841–5847.
39. Ishikawa K. Takenaga K. Akimoto M. Koshikawa N. Yamaguchi A. Imanishi H. et al. (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320: 661–664.
40. Itzkowitz S. Yio X. (2004) Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287: G7–G17.
41. Jang M. Cal L. Udeani G. Slowing K. Thomas C. Beecher C. et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 216–220.
42. Komarova N. Wodarz D. (2005) Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 102: 9714–9719.
43. Koukourakis M. Bentzen S. Giatromanolaki A. Wilson G. Daley F. Saunders M. et al. (2006) Endogenous markers of two separate hypoxia Response pathways (hypoxia inducible factor 2 and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24: 727–735.
44. Kovacic P. Osuna J. Jr (2000) Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr Pharm Des 6: 277–309.
45. Kozusko F. Bourdeau M. (2007) A unified model of sigmoid tumour growth based on cell proliferation and quiescence. Cell Prolif 40: 824-834.
46. Kune G. Kune S. Watson L. (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399–4404.
47. Langley R. (2013) Clinical evidence for the use of aspirin in the treatment of cancer. ecancer 7: 297. doi: 10.3332/ecancer.2013.297.
48. Lisanti M. Martinez-Outschoorn U. Chiavarina B. Pavlides S. Whitaker-Menezes D. Tsirigos A. et al. (2010) Understanding the ‘lethal’ drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy / mitophagy in the tumor microenvironment. Cancer Biol Ther 10: 537–542.
49. Liu P. Cheng H. Roberts T. Zhao J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627–644.
50. MacArthur M. Hold G. El-Omar E. (2004) Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286: G515–G520.
51. Maiti A. (2012) Reactive oxygen species reduction is a key underlying mechanism of drug resistance in cancer chemotherapy. Chemotherapy 1: 104. doi: 10.4172/cmt.1000104.
52. Martinez-Outschoorn U. Balliet R. Rivadeneira D. Chiavarina B. Pavlides S. Wang C. et al. (2010 a) Oxidative stress in cancer associated fibroblasts drives tumor stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9: 3256–3276.
53. Martinez-Outschoorn U. Pavlides S. Whitaker-Menezes D. Daumer K. Milliman J. Chiavarina B. et al. (2010 b). Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 9: 2423–2433.
54. Martinez-Outschoorn U. Trimmer C. Lin Z. Whitaker-Menezes D. Chiavarina B. Zhou J. et al. (2010 c) Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF 1 induction, and NF-κB activation in the tumor stromal microenvironment. Cell Cycle 9: 3515–3533.
55. McCowan C. Munro A. Donnan P. Steele R. (2013) Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 49: 1049–1057.
56. Mercier I. Casimiro M. Wang C. Rosenberg A. Quong J. Allen K. et al. (2008) Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther 7: 1212–1225.
57. Michor F. Iwasa Y. Lengauer C. Nowak M. (2005) Dynamics of colorectal cancer. Semin Cancer Biol 15: 484–493.
58. Miquel J. Bertoni-Freddari C. (2000) Causes and consequences of damage to mitochondria: morphological aspects. Methods Mol Med 38: 221–235.
59. Nechuta S. Lu W. Chen Z. Zheng Y. Gu K. Cai H. et al. (2011) Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 20: 262-271.
60. Nelson W. de Marzo A. de Weese T. Isaacs W. (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172: S6–S11.
61. Oberley L. (2001) Anticancer therapy by overexpression of superoxide dismutase. Antioxid Redox Signal 3: 461–472.
62. Oberley L. (2005) Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 59: 143–148.
63. Pai R. Soreghan B. Szabo I. Pavelka M. Baatar D. Tarnawski A. (2002) Prostaglandin E 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8: 289–293.
64. Pani G. Colavitti R. Bedogni B. Fusco S. Ferraro D. Borrello S. et al. (2004) Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr Med Chem 11: 1299–1308.
65. Pavlides S. Tsirigos A. Migneco G. Whitaker-Menezes D. Chiavarina B. Flomenberg N. et al. (2010 a) The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 9: 3485–3505.
66. Pavlides S. Tsirigos A. Vera I. Flomenberg N. Frank P. Casimiro M. et al. (2010 b) Transcriptional evidence for the ‘reverse Warburg effect’ in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease and ‘Neuron-Glia Metabolic Coupling’. Aging 2: 185–199.
67. Pavlides S. Tsirigos A. Vera I. Flomenberg N. Frank P. Casimiro M. et al. (2010 c) Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the ‘reverse Warburg effect’: a transcriptional informatics analysis with validation. Cell Cycle 9: 2201–2219.
68. Pavlides S. Whitaker-Menezes D. Castello-Cros R. Flomenberg N. Witkiewicz A. Frank P. et al. (2009) The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8: 3984–4001.
69. Peek R. Jr Blaser M. (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2: 28–37.
70. Pereg D. Lishner M. (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258: 115–123.
71. Philip M. Rowley D. Schreiber H. (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14: 433–439.
72. Pouysségur J. Dayan F. Mazure N. (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437–443.
73. Pritchard K. Shepherd L. Chapman J. Norris B. Cantin J. Goss P. et al. (2008) Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. JNCI J Natl Cancer Inst 100: 1581–1591.
74. Rolland P. Martin P. Jacquemier J. Rolland A. Toga M. (1980) Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64: 1061–1070.
75. Rothwell P. Fowkes F. Belch J. Ogawa H. Warlow C. Meade T. (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31–41.
76. Rothwell P. Price J. Fowkes F. Zanchetti A. Roncaglioni M. Tognoni G. et al. (2012 a) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602–1612.
77. Rothwell P. Wilson M. Elwin C. Norrving B. Algra A. Warlow C. et al. (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741–1750.
78. Rothwell P. Wilson M. Price J. Belch J. Meade T. Mehta Z. (2012 b) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379: 1591–1601.
79. Sharpe C. Collet J. McNutt M. Belzile E. Boivin J. Hanley J. (2000) Nested case–control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83: 112–120.
80. Sheng H. Shao J. Washington M. DuBois R. (2001) Prostaglandin E 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075–18081.
81. Singh R. Sudhakar A. Lokeshwar B. (2011) From normal cells to malignancy: distinct role of pro-inflammatory factors and cellular redox mechanisms. J Cancer Sci Ther 3: 70–75. doi: 10.4172/1948-5956.1000061.
82. Sloan E. Ciocca D. Pouliot N. Natoli A. Restall C. Henderson M. et al. (2009) Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 174: 2035–2043.
83. Stasinopoulos I. Mori N. Bhujwalla Z. (2013) The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. Front Pharmacol 4: 34. doi: 10.3389/fphar.2013.00034.
84. St Clair D. Zhao Y. Chaiswing L. Oberley T. (2005) Modulation of skin tumorigenesis by SOD. Biomed Pharmacother 59: 209–214.
85. Thomasset S. Berry D. Garcea G. Marczylo T. Steward W. Gescher A. (2007) Dietary polyphenolic phytochemicals – promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 120: 451–458.
86. Thun M. Henley S. Patrono C. (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252–266.
87. Thun M. Jacobs E. Patrono C. (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9: 259-267.
88. Trimmer C. Sotgia F. Whitaker-Menezes D. Balliet R. Eaton G. Martinez-Outschoorn U. et al. (2011) Caveolin-1 and mitochondrial SOD 2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther 11: 383–394.
89. Ulrich C. Bigler J. Potter J. (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6: 131–140.
90. Venkataraman S. Jiang X. Weydert C. Zhang Y. Zhang H. Goswami P. et al. (2005) Manganese superoxide dismutase overexpression inhibits the growth of androgen independent prostate cancer cells. Oncogene 24: 77–89.
91. Walsh A. Cook R. Manning H. Hicks D. Lafontant A. Arteaga C. et al. (2013) Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res 73: 6164–6174.
92. Wardman P. (2001) Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 8: 739–761.
93. Watson J. (2013) Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3: 2046–2441.
94. Witkiewicz A. Dasgupta A. Nguyen K. Liu C. Kovatich A. Schwartz G. et al. (2009 a) Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 8: 1167–1175.
95. Witkiewicz A. Dasgupta A. Sammons S. Er O. Potoczek M. Guiles F. et al. (2010) Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 10: 135–143.
96. Witkiewicz A. Dasgupta A. Sotgia F. Mercier I. Pestell R. Sabel M. et al. (2009 b) An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 174: 2023–2034.
97. Zaorsky N. Buyyounouski M. Li T. Horwitz E. (2012) Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys 84: e13–e17.
98. Zhong W. Oberley L. Oberley T. St Clair D. (1997) Suppression of the malignant phenotype of human glioma cells by overexpression of manganese superoxide dismutase. Oncogene 14: 481–490.